FCM
XLRN

Frontier Capital Management’s Acceleron Pharma XLRN Stock Holding History

Frontier Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,030
Closed -$2.24M – 294
2021
Q3 		$2.24M Sell
13,030
-39,264
-75% -$5.14M 0.02% 268
2021
Q2 		$6.56M Sell
52,294
-96,618
-65% -$12.2M 0.05% 260
2021
Q1 		$20.2M Sell
148,912
-70,669
-32% -$9.13M 0.15% 169
2020
Q4 		$28.1M Buy
219,581
+78,569
+56% +$9.21M 0.21% 162
2020
Q3 		$15.9M Buy
141,012
+102,288
+264% +$10.2M 0.14% 183
2020
Q2 		$3.69M Sell
38,724
-51
-0.1% -$4.92K 0.03% 273
2020
Q1 		$3.48M Buy
+38,775
New +$3.01M 0.04% 255

Frontier Capital Management's XLRN Position: Q4 2021 in Review

Frontier Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 13,030 shares — an estimated $2.24M sold.

Frontier Capital Management first reported a position in XLRN in Q1 2020 and held it in 7 quarters. The position peaked at $28.1M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Frontier Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Frontier Capital Management sold 13,030 Acceleron Pharma shares in Q4 2021, an estimated $2.24M.
  • Frontier Capital Management first reported a position in Acceleron Pharma in Q1 2020 and held it in 7 quarters.
  • Frontier Capital Management's Acceleron Pharma position peaked at $28.1M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Frontier Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.